Actinomycin D Specifically Reduces Expanded CUG Repeat RNA in Myotonic Dystrophy Models

Area of Science:

• Genetics
• Molecular Biology
• Pharmacology

Background:

• Myotonic dystrophy type 1 (DM1) is an inherited neuromuscular disorder.
• DM1 is caused by toxic transcription of expanded CTG repeats.
• Current treatments focus on symptom management, not addressing the genetic cause.

Purpose of the Study:

• To investigate Actinomycin D (ActD) as a potential therapeutic agent for DM1.
• To determine if ActD can reduce toxic CTG repeat transcription in DM1 models.
• To assess ActD's effect on DM1-associated splicing defects.

Main Methods:

• Utilized DM1 cell and mouse models.
• Administered ActD at varying concentrations.
• Quantified CUG transcript levels.
• Analyzed splicing defects using RNA sequencing (RNA-seq).

Main Results:

• ActD decreased CUG transcript levels in a dose-dependent manner in DM1 models.
• Low, nanomolar concentrations of ActD were effective.
• ActD reversed DM1-associated splicing defects within the human therapeutic range.
• RNA-seq confirmed low ActD doses did not globally inhibit transcription.

Conclusions:

• Transcription inhibition of CTG expansions is a viable therapeutic strategy for DM1.
• ActD demonstrates potential as a DM1 treatment by targeting toxic repeat transcription.
• Low-dose ActD offers a targeted approach to DM1 therapy without broad transcriptional suppression.